Financial Data and Key Metrics Changes - Total revenue for the second quarter was $203.1 million, up 1% year over year, aligning with expectations when excluding the impact of Rite Aid [24] - Adjusted EBITDA for the quarter was $69.4 million, a 6% increase year over year, resulting in an adjusted EBITDA margin of 34.2%, an improvement of 160 basis points compared to the same period last year [26] - The company closed the quarter with $281.3 million in cash and repurchased approximately $46.4 million worth of shares at an average price of $4.53 per share [27] Business Line Data and Key Metrics Changes - Revenue from pharma manufacturer solutions was $35 million, up 32% year over year, indicating strong performance and a projected growth of 30% or higher for 2025 [25][20] - Prescription transaction revenue declined by 3% year over year, primarily due to the impact of Rite Aid and the erosion of the ISP program [24][28] Market Data and Key Metrics Changes - The company noted a decline in monthly active consumers, which is expected to continue in the short term due to the transition from traditional retail transactions to consumer direct price points [24][25] - The healthcare landscape is changing, with Congress passing a budget bill that cuts funding for Medicaid and individual exchange products, potentially leaving nearly 10 million people uninsured [13] Company Strategy and Development Direction - The company is focused on strengthening relationships with pharma manufacturers and expanding its share of wallet across market access, consumer marketing, and HCP budgets [6] - GoodRx is enhancing its integrated savings program to service brand medications in addition to generics, aiming to deepen engagement with consumers [8] - The launch of a condition subscription product for erectile dysfunction is part of the strategy to maximize returns on existing capabilities and deepen consumer engagement [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to respond to changes in the healthcare landscape and emphasized the importance of GoodRx in providing access to affordable medications [10][15] - The company acknowledged short-term negative impacts from Rite Aid's bankruptcy and a decline in volume from one of its PBM partners but remains optimistic about long-term growth opportunities [11][28] Other Important Information - The company is actively advocating for policies that expand access to affordable medication and is engaged with government entities exploring models to reduce brand drug pricing directly to consumers [16][15] - The launch of GoodRx Community Link aims to support independent pharmacies by providing predictable pricing and favorable economics [18] Q&A Session Summary Question: Can you elaborate on the ISP and new partnerships? - Management acknowledged the importance of ISP and noted that while expectations should be tempered, they are adding new partners and expanding the program [34][36] Question: How do you view the growth of Manufacturer Solutions? - Management expressed confidence in achieving 30% revenue growth for Manufacturer Solutions, driven by strong ROI studies and engagement with pharma partners [44][48] Question: What is the impact of Rite Aid and ISP on guidance? - Management indicated that the revenue impact from Rite Aid and ISP is roughly half and half, with ongoing efforts to recapture consumers affected by Rite Aid's closures [72][74] Question: Are there shifts in consumer behavior affecting platform usage? - Management noted that rising consumer prices have pushed more transactions into funded benefits, impacting monthly active consumer counts, but they expect tailwinds to return in the future [96][97] Question: What proactive actions are being taken regarding ISP? - Management emphasized the importance of adding more commercial lives and expanding partnerships to grow the ISP program despite challenges with one particular partner [99][101]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $203 million, reflecting a 3% increase year-over-year [25] - Prescription transaction revenue and manufacturer solutions revenue increased by 217% year-over-year [25] - Adjusted EBITDA for Q1 2025 was $69.8 million, an 11% increase year-over-year, with an adjusted EBITDA margin of 34.4% [25] Business Line Data and Key Metrics Changes - The prescription marketplace and manufacturer solutions offerings saw significant growth, with a focus on enhancing partnerships with pharmacies and pharmaceutical manufacturers [10][18] - The integrated savings program (ISP) is being evaluated for expansion into non-covered medications, indicating a strategic shift to enhance value [17] Market Data and Key Metrics Changes - Over 12 million consumers and 750,000 healthcare professionals (HCPs) utilized GoodRx in Q1 2025, demonstrating strong platform engagement [9] - The company noted ongoing uncertainty in the macroeconomic environment, including regulatory changes and consumer sentiment shifts, which could impact business [11] Company Strategy and Development Direction - The company is focused on high-impact initiatives to strengthen its position in the pharmacy ecosystem, including leadership changes and strategic partnerships [5][6] - GoodRx aims to enhance its e-commerce capabilities and integrate more deeply with pharmacy operations to improve consumer experience and pharmacy profitability [16][21] - The company is committed to investing in its brand and expanding its value proposition to consumers and HCPs [13][22] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by the Rite Aid bankruptcy and emphasized the importance of maintaining relationships with pharmacy partners to ensure smooth transitions for consumers [11][12] - The company remains optimistic about its future growth opportunities, particularly in expanding its partnerships and enhancing its service offerings [20][22] Other Important Information - The company ended Q1 2025 with $301 million in cash and $91.7 million of unused capacity on its revolving line of credit, indicating strong liquidity [25] - A share repurchase program is in place, with approximately $189 million remaining under the $450 million authorization [25] Q&A Session Summary Question: What are the most important high-impact initiatives for the company? - Management highlighted closer partnerships with retail pharmacies and expanding brand partnerships as key initiatives to drive growth [36] Question: How has the company historically managed store closures and consumer retention? - Management indicated that they are actively working to ensure smooth transitions for consumers during pharmacy closures, emphasizing the strength of the GoodRx brand [42][45] Question: What is the impact of the shift to cost-plus pricing by larger PBMs on the company's legacy model? - Management stated that a significant portion of their business already operates on cost-plus pricing, and they remain indifferent to the reimbursement mechanism [54] Question: Is there still an opportunity with GLP medications? - Management confirmed that opportunities with GLP medications continue to exist, and they are in discussions with manufacturers to enhance consumer access [58] Question: How does the company view its exposure to Medicare beneficiaries? - Management noted that less than 30% of users are Medicare eligible, and the impact of changes in Medicare out-of-pocket costs is minimal [93][95] Question: What is the company's strategy regarding biosimilars? - Management expressed optimism about the uptake of biosimilars and their alignment with the company's affordability narrative [97]

Financial Data and Key Metrics Changes - For Q4 2024, revenue was $198.6 million, and adjusted EBITDA was $67.1 million, leading to a full year revenue of $792.3 million, a 6% increase year-over-year on a GAAP basis [29] - Full year adjusted EBITDA was $260.2 million, representing a 20% growth over 2023 [30] - Net income for 2024 was $16.4 million compared to a net loss of $8.9 million in 2023, while adjusted net income increased to $131.6 million from $114.6 million in 2023 [30][31] - Adjusted EBITDA margin improved to 32.8%, marking another year of margin expansion [30][32] Business Line Data and Key Metrics Changes - Prescription transactions revenue grew 5% year-over-year to $577.5 million, primarily due to a 7% increase in monthly active consumers [29][30] - Subscription revenue declined 8% to $86.5 million, largely due to the sunset of a retailer-specific prescription savings program [30] - Pharma manufacturer solutions revenue increased by 26% year-over-year to $107.2 million [30] Market Data and Key Metrics Changes - Nearly 30 million consumers used GoodRx in 2024, saving approximately $17 billion on medications, with a 3% year-over-year growth in the prescription discount segment [14][29] - The company's share of the prescription discount segment grew by 3% year-over-year in Q4 2024 [14] Company Strategy and Development Direction - The company aims to enhance the prescription experience for consumers and healthcare professionals, focusing on reducing friction and improving access to medications [10][12] - GoodRx is expanding its Integrated Savings Program (ISP) to include non-covered brands, addressing gaps in coverage and enhancing value for consumers and healthcare professionals [17][25] - The company is also increasing its partnerships with pharma manufacturers, growing from 150 to over 200 brands in 2024, and focusing on integrated access solutions and e-commerce capabilities [18][20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the opportunities to make healthcare more affordable and accessible, particularly in light of potential regulatory changes favoring transparency and lower prices [13][28] - The company anticipates revenue growth in 2025 to be in the range of $810 million to $840 million, representing approximately 4% growth at the midpoint [33] - Management acknowledged potential headwinds from pharmacy store closures but remains confident in the overall growth trajectory of prescription transaction revenue [102] Other Important Information - The company has a strong balance sheet with $448.3 million in cash on hand and $500 million in outstanding debt, providing significant liquidity [32] - GoodRx is committed to returning excess cash to shareholders through share repurchases, with $290 million authorized for spend [75] Q&A Session Summary Question: How many new initiatives are included in the guidance? - Management indicated that the guidance accounts for some expansion in manufacturer programs and marketplace growth, particularly in brand expansion [39][40] Question: Can you comment on the pharma manufacturing solutions growth? - Management remains confident in achieving 20% growth in pharma manufacturer solutions, citing a significant increase in partnerships and validated results [48][49] Question: What is the current status of ISP rollouts with PBM partners? - Management noted ongoing discussions with PBM partners and emphasized the importance of wrapping non-covered brands to enhance value [56][58] Question: What are the headwinds reflected in the guidance? - Management acknowledged potential headwinds from pharmacy store closures but expects overall growth in prescription transaction revenue [102]